# LITT and Pembrolizumab in Recurrent Brain Metastasis

> **NCT04187872** · PHASE1 · TERMINATED · sponsor: **University of Florida** · enrollment: 10 (actual)

## Conditions studied

- Melanoma
- Non-small Cell Lung Carcinoma (NSCLC)
- Renal Cell Carcinoma (RCC)
- Small-cell Lung Cancer
- Head and Neck Squamous Cell Cancer
- Classical Hodgkin Lymphoma
- Primary Mediastinal Large B-Cell Lymphoma
- Urothelial Carcinoma
- Microsatellite Instability-High Cancer
- Gastric Cancer
- Esophageal Cancer
- Cervical Cancer
- Hepatocellular Carcinoma
- Merkel Cell Carcinoma
- Brain Metastases, Adult

## Interventions

- **COMBINATION_PRODUCT:** LITT + Pembrolizumab

## Key facts

- **NCT ID:** NCT04187872
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-10
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor terminated
- **Last updated:** 2023-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04187872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04187872, "LITT and Pembrolizumab in Recurrent Brain Metastasis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04187872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*